Foshan Deruike Pharmaceutical

Foshan Deruike Pharmaceutical is a specialized pharmaceutical company based in Foshan, China, focused on the research, development, and commercialization of high-end generic drugs and improved therapeutic formulations. Founded in 2016, the company leverages advanced drug delivery system (DDS) technologies, including sustained-release, controlled-release, and complex solubilization techniques, to enhance the clinical performance of small molecule therapeutics. Their portfolio primarily targets the cardiovascular, central nervous system, and endocrine therapeutic areas, with several products such as apremilast and vortioxetine having reached the commercial stage in the Chinese market. Deruike operates as a National High-tech Enterprise, providing integrated R&D services and technology transfer to domestic pharmaceutical partners. The company maintains a strong focus on high-barrier generics, utilizing its pilot plant and industrialization base to bridge the gap between laboratory research and large-scale production.